---
name: Critical Path Institute
slug: critical-path-institute
site: cro
website_domain: c-path.org
summary: Critical Path Institute convenes pharmaceutical, government, patient, and academic organizations to optimize drug and medical product development through collaborative consortia, regulatory science initiatives, and clinical trial design optimization.
tagline: Optimizing drug development through multi-stakeholder collaboration and regulatory science.
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: 
tier2_domain_verified: false
updated_at: 2026-07-17T13:00:14.629Z
services_count: 4
modalities_count: 0
indications_count: 4
locations_count: 0
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# Critical Path Institute

Optimizing drug development through multi-stakeholder collaboration and regulatory science.

Listed on cro.directory.

## Summary

Critical Path Institute convenes pharmaceutical, government, patient, and academic organizations to optimize drug and medical product development through collaborative consortia, regulatory science initiatives, and clinical trial design optimization.

## Services

- Regulatory Affairs
- US FDA Regulatory Strategy
- Clinical Operations
- Translational Research

## Indications

- Neurology
- Metabolic
- Rare Disease
- Immunology

## Long description

Critical Path Institute (C-Path) is a non-profit organization that optimizes drug and medical product development lifecycles by convening stakeholders across the pharmaceutical industry, government agencies, patient communities, and academic institutions.

C-Path operates disease-specific and cross-functional consortia that address critical gaps in drug development:

- **Critical Path for Alzheimer's Disease** — develops tools to optimize clinical trial designs, identify individuals best suited for trials, and define meaningful benefits for early-stage disease.
- **Type 1 Diabetes (T1D) Consortium** — translates scientific findings into actionable insights for decision-makers advancing therapeutic initiatives.
- **Duchenne Regulatory Science Consortium (D-RSC)** — focuses on regulatory science and accessibility for Duchenne muscular dystrophy development.
- **ALS Research and Clinical Trial Design** — addresses fragmented efforts by fostering collaboration among the FDA, NIH, C-Path, and patient advocates.
- **CP-RND (Critical Path – Rare & Neglected Diseases)** — a collaboration with the FDA and NIH to accelerate development through natural history data collection.

C-Path's mission is to make a difference for patients and their families by bridging communication gaps between scientists, regulators, industry, and patient communities, enabling more efficient and patient-centric drug development.

## Related companies

- [CovarsaDx](/companies/covarsadx) (Regulatory Affairs, US FDA Regulatory Strategy) — [Compare](/compare/covarsadx/critical-path-institute)
- [Inizio Ignite](/companies/creativ-ceutical) (Regulatory Affairs, Clinical Operations) — [Compare](/compare/creativ-ceutical/critical-path-institute)
- [Beaufort](/companies/beaufortcro) (Regulatory Affairs, Clinical Operations) — [Compare](/compare/beaufortcro/critical-path-institute)
- [Datavant](/companies/aetion) (Regulatory Affairs, Clinical Operations) — [Compare](/compare/aetion/critical-path-institute)
- [Proxima Clinical Research](/companies/proximacro) (Regulatory Affairs, US FDA Regulatory Strategy) — [Compare](/compare/critical-path-institute/proximacro)
- [Parexel](/companies/parexel) (Regulatory Affairs, US FDA Regulatory Strategy) — [Compare](/compare/critical-path-institute/parexel)
- [Optum Life Sciences](/companies/optum) (Regulatory Affairs, Clinical Operations) — [Compare](/compare/critical-path-institute/optum)
- [Aldeyra Therapeutics](/companies/aldeyra) (US FDA Regulatory Strategy, Clinical Operations) — [Compare](/compare/aldeyra/critical-path-institute)

_Profile last updated: 2026-07-17T13:00:14.629Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.